Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free public preview Track APGE with free AI briefings, catalyst countdowns, and dilution alerts.

APGE — Apogee Therapeutics, Inc.

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$105.6M Cash on Hand
5mo Cash Runway
7.2% Short Interest

🧪 Upcoming Trial Catalysts

📊 Drug Pipeline

DrugIndicationPhaseStatus
APG777 Atopic Dermatitis PHASE2 ACTIVE_NOT_RECRUITING
APG990 Atopic Dermatitis PHASE1 ACTIVE_NOT_RECRUITING
Dupilumab Atopic Dermatitis PHASE1 ACTIVE_NOT_RECRUITING

💰 Cash Runway & Dilution Risk

APGE holds $105.6M in cash and burns about $63.5M/quarter from operations, giving an estimated runway of 5 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for APGE free →

📈 Recent Insider Activity (Form 4)

DateInsiderTypeValue
2026-08-11 Fairmount Funds Management L
Purchase $5.6M
2026-08-11 Fairmount Funds Management L
Purchase $14.9M
2026-08-11 Fairmount Funds Management L
Sale $0
2026-08-07 Dambkowski Carl
Purchase $4M
2026-08-07 Dambkowski Carl
Sale $22.6M

Get the full APGE picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for APGE and 2 more tickers of your choice.

Create Free Account →
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.